Search

Objective: The coronavirus disease 2019 pandemic has been resulting in increased hospital occupancy rates. Rheumatic patients cannot still reach to hospitals, or they hesitate about going to a hospital even they are able to reach. We aimed to show the effect of the first wave of coronavirus disease 2019 pandemic on the treatment of biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis or spondyloarthritis. Methods: Patients were divided into three groups as follows: pre-pandemic (Pre-p: starting on biological disease-modifying anti-rheumatic drug therapy for the first time within 6 months before March 11, 2020); post-pandemic A (Post-p A: starting on biological disease-modifying anti-rheumatic drug therapy for the first time within the first 6 months after March 11, 2020); post-pandemic B (Post-p B: starting on biological disease-modifying anti-rheumatic drug therapy for the first time within the second 6 months). Results: The number of rheumatoid arthritis patients in the Post-p A and B groups decreased by 51% and 48%, respectively, as compared to the Pre-p group similar rates of reduction were also determined in the number of spondyloarthritis patients. The rates of tofacitinib and abatacept use increased in rheumatoid arthritis patients in Post-p period. Conclusion: The number of rheumatoid arthritis and spondyloarthritis patients starting on biological disease-modifying anti-rheumatic drugs for the first time decreased during the first year of the coronavirus disease 2019 pandemic. [ABSTRACT FROM AUTHOR]

Background: This study aimed to examine fetomaternal outcomes in pregnant women in a large Turkish Takayasu arteritis (TAK) cohort and to evaluate the effects of pregnancy on the disease in those patients. Methods: This is a cohort study involving 296 pregnancies of 112 TAK patients from 8 tertiary rheumatology centers in Turkey. Pregnancies were divided into 2 groups as pre‐d (before disease onset) and post‐d (after disease onset). In addition, post‐d pregnancies were further divided into 2 subgroups according to fetomaternal complications (FMC) development status. Finally, patients were grouped into those with and without a history of pregnancy after disease onset. Results: In post‐d pregnancies, rates of worsening hypertension, new‐onset hypertension, and preeclampsia were higher than in pre‐d pregnancies (0.9% vs 16%, P <.001, 0.5% vs 5.3%, P =.012, and 0% vs 4%, P =.013, respectively). Patients with FMC were more likely to have renal artery involvement (65% vs 21%, P =.003). The patients who had post‐d were younger, had longer disease duration, and had more relapses number than other patients (P <.001, P =.028, P =.016, respectively). Vasculitis Damage Index (VDI) results were similar in patients with or without post‐d pregnancies. Conclusion: Pregnancies after disease onset were found to be associated with HT and preeclampsia/eclampsia. HT‐related FMCs are increased in TAK, and patients with renal artery involvement are at higher risk. The number of relapses increases in patients who become pregnant after disease onset, but pregnancy was not an independent risk factor for relapse. Pregnancy after the onset of disease had no negative effect on VDI. [ABSTRACT FROM AUTHOR]

Amaç: Geriatrik yaş grubundaki romatoid artrit (RA) ve psoriatik artrit (PsA) hastalarında konvansiyonel DMARD sonrası ilk tercih edilen biyolojik veya hedefe yönelik sentetik hastalık modifiye edici antiromatizmal ilaçlar (bDMARD'lar ve tsDMARD'lar) iyi çalışılmamıştır. Bu çalışmada, romatoid artrit ve psoriatik artritli geriatrik ve genç erişkin popülasyonda konvansiyonel DMARD sonrası ilk tercih edilen bDMARD veya tsDMARD'lar arasındaki farklılıkların ve ilaçta kalımın araştırılması hedeflenmiştir. Yöntem: TReasure, 2017 yılında oluşturulan Türkiye'nin farklı bölgelerindeki 17 romatoloji merkezi tarafından RA ve spondiloartrit (SpA) hastalarından veri toplamak için oluşturulan web tabanlı, çok merkezli bir veri tabanıdır. Bu çalışmada TReasure veri tabanından toplanan RA'lı 3136 ve PsA'lı 738 hasta değerlendirmeye alınmıştır. İlk tercih edilen bDMARD veya tsDMARD, tanımlayıcı istatistiksel yöntemle, ilaçta kalım Kaplan-Meier yöntemi ile değerlendirilmiştir. Bulgular: RA'lı hastaların %12'si geriatrik popülasyondaydı. Altmış beş yaş altındaki RA'lı hastalarda konvansiyonel DMARD sonrası romatoloji uzmanları tarafından ilk tercih edilen bDMARD/tsDMARD'lara bakıldığında, sırasıyla adalimumab (%20,6), etanersept (%19,9) ve tofasitinib (%13,6) olduğu gözlenirken, ≥65 yaşta sırasıyla rituksimab (%24), tofasitinib (%20,9) ve etanersept (%13) tercih edilmiştir. PsA hastalarının %3'ü 65 yaş ve üzerindeydi. Altmış beş yaş altındaki PsA hastalarında konvansiyonel DMARD sonrası ilk başlanan ilaçlar sırasıyla adalimumab (%41,1), etanersept (%17,6) ve infliksimab (%15,5); ≥65 yaşta ise sırasıyla adalimumab (%28,6), etanersept (%17,9) ve sertolizumab (%17,9) olduğu gözlenmiştir. RA grubunda, 65 yaş ve üzeri hastalarda; PsA grubunda ise 65 yaş altı hastalarda ilaçta kalım daha uzun olarak saptanmıştır. Sonuç: Hastanın yaşının hekimin ilk bDMARD/tsDMARD seçimini etkileyebildiği görülmüştür. Altmış beş yaş altı RA hastalarında ilk anti-TNFα ilaçlar tercih edilirken 65 yaş ve üstü hastalarda ilk sırada rituksimab ve tofasitinib tercih edilmiştir. PsA'lı hem yaşlı hem de genç hastalarda ilk olarak anti-TNFα tercih edilmiştir. Rituksimab ve tofasitinibin PsA da kullanımının sınırlı olduğu göz önüne alınmalıdır. İlacın uygulanım şekillerinin (rituksimabın uzun aralıklarla hastane kontrolünde, tofasitinibin oral kullanımı) geriatrik popülasyonda romatologların ilaç seçimini etkileyebileceği sonucuna varılmıştır. [ABSTRACT FROM AUTHOR]

Copyright of Journal of Turkish Society for Rheumatology is the property of Galenos Yayinevi Tic. LTD. STI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Journal of Turkish Society for Rheumatology is the property of Galenos Yayinevi Tic. LTD. STI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Copyright of Journal of Turkish Society for Rheumatology is the property of Galenos Yayinevi Tic. LTD. STI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)

Objectives: To analyse the clinical and laboratory factors associated with bamboo spine., Methods: Data of patients fulfilling the 2009 ASAS classification criteria for axial spondyloarthritis, registered in the national, multicentre, longitudinal, and observational database of TReasure was analysed. Radiographs were assessed using the Bath Ankylosing Spondylitis Radiologic Index (BASRI). Data of patients with a bamboo spine (Group 1) was compared to data derived from patients with a longstanding disease of at least 15 years but no syndesmophytes (Group 2)., Results: Out of the 5060 patients, 1246 had eligible radiographs. There were 111 patients (8.9%) with a bamboo spine. Male sex was more common among patients with bamboo spine. The median BMI of 27.7 (25.8-31.1) in Group1 was higher than the BMI of 25.9 (22.9-29.2) in Group 2 (p<0.001). Hip arthritis, present or documented by a physician, was more common in Group 1 [(58/108 (53.7%) vs. 35/103 (34%), p=0.004]. There was a tendency towards a more prevalent enthesitis in these patients [29.1% (25/86) vs. 15.9%(11/69), p=0.054]. HLA-B27 status did not differ between groups. Smoking was more prevalent in Group 1. Multivariate logistic regression analysis revealed that male sex, body mass index, hip arthritis, and enthesitis are associated with bamboo spine in axSpA., Conclusions: Bamboo spine was more common in the male sex and associated with a delay in diagnosis, high BMI, hip involvement, and enthesitis. The constellation of increased body weight, hip arthritis, and enthesitis may imply that mechanical stress contributes to radiographic damage in the presence of chronic inflammation.

Objective: The coronavirus disease 2019 pandemic has been resulting in increased hospital occupancy rates. Rheumatic patients cannot still reach to hospitals, or they hesitate about going to a hospital even they are able to reach. We aimed to show the effect of the first wave of coronavirus disease 2019 pandemic on the treatment of biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis or spondyloarthritis., Methods: Patients were divided into three groups as follows: pre-pandemic (Pre-p: starting on biological disease-modifying anti-rheumatic drug therapy for the first time within 6 months before March 11, 2020); post-pandemic A (Post-p A: starting on biological disease-modifying anti-rheumatic drug therapy for the first time within the first 6 months after March 11, 2020); post-pandemic B (Post-p B: starting on biological disease-modifying anti-rheumatic drug therapy for the first time within the second 6 months)., Results: The number of rheumatoid arthritis patients in the Post-p A and B groups decreased by 51% and 48%, respectively, as compared to the Pre-p group similar rates of reduction were also determined in the number of spondyloarthritis patients. The rates of tofacitinib and abatacept use increased in rheumatoid arthritis patients in Post-p period., Conclusion: The number of rheumatoid arthritis and spondyloarthritis patients starting on biological disease-modifying anti-rheumatic drugs for the first time decreased during the first year of the coronavirus disease 2019 pandemic.